CagriSema: Novo Nordisk's Semaglutide + Amylin Combination
Complete guide to CagriSema, the combination of semaglutide and cagrilintide (a long-acting amylin analog). Learn about clinical trial results showing up to 25% weight loss, mechanism of action, and expected availability.
More on Pipeline Drugs
The Science of Dual Hormone Targeting
The human body regulates appetite and metabolism through multiple overlapping hormone systems. Current GLP-1 medications target one of these systems with remarkable success. CagriSema represents the next evolution: simultaneously targeting two complementary systems to achieve results that neither could alone.
Semaglutide activates GLP-1 receptors in the brain, gut, and pancreas, reducing appetite, slowing gastric emptying, and improving insulin secretion. Cagrilintide activates amylin receptors in the brain's area postrema and nucleus tractus solitarius — regions that control satiety — producing an additive appetite-reducing effect through a distinct neurological pathway.
Think of it as addressing hunger through two different "channels" in the brain. Some patients who plateau on semaglutide alone may respond to the additional amylin signaling, and the combined effect produces deeper, more sustained appetite suppression.
REDEFINE Trial Results
REDEFINE 1: Obesity Without Diabetes
The flagship trial enrolled adults with obesity (BMI 30+) or overweight with comorbidities. Results at 68 weeks showed CagriSema producing approximately 22.7% average body weight loss compared to 15.8% for semaglutide alone and 8.1% for cagrilintide alone. The combination clearly exceeded either component, confirming the additive benefit of dual targeting.
Approximately 50% of CagriSema patients achieved 25% or greater weight loss, a threshold that approaches the results of bariatric surgery. This level of weight loss produces dramatic improvements in nearly every obesity-related health condition.
REDEFINE 2: Type 2 Diabetes
In patients with type 2 diabetes, CagriSema demonstrated both superior weight loss and glycemic control compared to semaglutide alone. A1C reductions were approximately 2.2 percentage points, and weight loss was approximately 16% (lower than in non-diabetic patients, consistent with the pattern seen across all GLP-1 studies). The diabetes population results support a broad metabolic benefit beyond weight loss.
Additional REDEFINE Studies
The program includes trials evaluating CagriSema versus tirzepatide head-to-head, long-term maintenance, and special populations. These studies will provide the data needed for comprehensive labeling and help determine where CagriSema fits in the treatment landscape relative to existing options.
How CagriSema Is Administered
CagriSema is designed as a single once-weekly subcutaneous injection using a pre-filled pen, similar in concept to current Wegovy or Zepbound pens. Key administration details:
- Dosing: Once weekly, on the same day each week
- Titration: Gradual dose escalation over several weeks to minimize GI side effects, similar to current GLP-1 protocols
- Injection sites: Abdomen, thigh, or upper arm, rotating sites as with other injectables
- Storage: Refrigerated before first use, with room temperature storage for a limited period after opening
- Convenience: Both drugs delivered in a single injection rather than requiring two separate injections
Side Effects and Safety
CagriSema's side effect profile is generally consistent with other GLP-1 medications, though the dual mechanism means some effects may be modestly more common:
- Gastrointestinal: Nausea, vomiting, diarrhea, and constipation remain the most common side effects. The slow titration schedule helps minimize these. Most GI effects are transient and resolve within the first few months.
- Injection site reactions: Mild reactions were reported at rates similar to semaglutide alone.
- Hypoglycemia: Low blood sugar risk is increased when combined with insulin or sulfonylureas, as with other GLP-1 medications.
- Discontinuation rates: In REDEFINE trials, the discontinuation rate due to adverse events was modestly higher than semaglutide alone but remained acceptable.
Longer-term safety data will continue to accumulate as the trial program matures and post-marketing surveillance begins after approval. Learn about how GLP-1 medications work and what monitoring is needed.
CagriSema vs Current Options
How does CagriSema stack up against what is currently available?
vs. Semaglutide (Wegovy) 2.4mg
CagriSema consistently produces approximately 5-7 percentage points more weight loss than semaglutide alone. For a 250-pound patient, this translates to roughly 13-18 additional pounds lost. The difference is clinically meaningful and may be particularly important for patients with higher BMIs who need more substantial weight loss.
vs. Tirzepatide (Zepbound) 15mg
Tirzepatide at the highest dose produces approximately 20-22% weight loss. CagriSema's results overlap with tirzepatide's upper range. Head-to-head trial data will clarify the relative efficacy. Both represent a significant step beyond semaglutide alone, and the choice between them may depend on individual response, side effect tolerance, and insurance coverage.
vs. Bariatric Surgery
Gastric sleeve surgery typically produces 25-30% weight loss, and gastric bypass produces 30-35%. CagriSema's 22-25% average approaches the lower end of surgical outcomes, making it a compelling non-surgical alternative for many patients. However, medication requires ongoing use, while surgery is a one-time procedure.
Medical Disclaimer: This article discusses a medication that may not yet have received FDA approval at the time of reading. Clinical trial results may not fully predict real-world outcomes. Always consult your healthcare provider about the most appropriate treatment for your individual situation.
Frequently Asked Questions
What is CagriSema?
CagriSema is a once-weekly injectable combination of two drugs in a single pen: semaglutide (a GLP-1 receptor agonist, the active ingredient in Wegovy) and cagrilintide (a long-acting amylin analog). By targeting two different appetite and metabolism pathways simultaneously, CagriSema produces greater weight loss than either component alone.
How much weight loss does CagriSema produce?
In the Phase 3 REDEFINE trials, CagriSema produced average weight loss of approximately 22-25% of body weight at 68 weeks, depending on the study population. This exceeds the approximately 15-17% typically seen with semaglutide alone and is among the highest weight loss results seen with any single injectable medication.
When will CagriSema be available?
Novo Nordisk has submitted CagriSema for regulatory review, with FDA approval potentially coming in 2026. Manufacturing scale-up is underway, but actual availability will depend on approval timing, manufacturing capacity, and market launch strategy. Initial availability may be limited, similar to the early days of Wegovy and Zepbound.
What is amylin and how does cagrilintide work?
Amylin is a hormone co-secreted with insulin by pancreatic beta cells after eating. It promotes satiety, slows gastric emptying, and suppresses glucagon. Cagrilintide is a synthetic long-acting version of amylin that maintains these effects throughout the week. Combined with semaglutide's GLP-1 effects, it creates a more complete appetite suppression and metabolic improvement signal.
Will CagriSema be more expensive than Wegovy?
Pricing has not been officially announced, but combination drugs are typically priced higher than single-agent products. However, competitive pressure from tirzepatide (Zepbound) and upcoming oral options may moderate pricing. The greater efficacy may also improve the cost-effectiveness argument for insurance coverage.
Begin Your Weight Loss Journey Today
Effective GLP-1 treatment is available now while next-gen options are in development.
Get Started TodaySources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).